WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society of Microbiology (ASM) Microbe 2018 Conference, taking place June 7-11 in Atlanta, GA. Presentations will include clinical and preclinical data on ETX2514, a novel broad spectrum β-lactamase inhibitor being developed in combination with sulbactam to treat Acinetobacter baumannii infections, and ETX0282, a novel, broad spectrum oral β-lactamase inhibitor being developed in combination with cefpodoxime proxetil to treat infections caused by multidrug-resistant (MDR) Gram-negative pathogens, including multidrug-resistant and carbapenem-resistant Enterobacteriaceae (CRE).
The details of the presentations are as follows:
ETX2514 Presentations:
Oral Presentation: Plasma and Intrapulmonary Concentrations of
ETX2514 and Sulbactam in Healthy Adult Subjects
Session: 529
- Real Time Tissue Pharmacokinetic Monitoring
Date and Time: June
11, 2018 11:30 AM – 11:45 AM
Location: A410
Poster #517: Plasma and Intrapulmonary Concentrations of ETX2514
and Sulbactam in Healthy Adult Subjects
Session: 409 - AAR04
- Antimicrobial PK/PD & General Pharmacology: Clinical Studies
Date
and Time: June 10, 2018 12:45 PM – 2:45 PM
Location:
Exhibit and Poster Hall, Building B, Halls B2-B5
Poster #604: Restoration of Sulbactam Activity by the Novel
β-lactamase inhibitor ETX2514 against recent clinical isolates of Acinetobacter
baumannii, including extensively drug-resistant (XDR) isolates
expressing OXA-237
Session: 062 - AAR08 - New Antimicrobial
Agents and New Research Technologies: New β-lactamase Inhibitors and
Inhibitor Combinations
Date and Time: June 8, 2018 11:00 AM
– 1:00 PM
Location: Exhibit and Poster Hall, Building B,
Halls B2-B5
Poster #605: The combination of ETX2514, a novel
diazabicyclooctenone β-lactamase inhibitor (BLI), and sulbactam
overcomes carbapenem resistant Acinetobacter baumannii (CRAB)
Session:
062 - AAR08 - New Antimicrobial Agents and New Research Technologies:
New β-lactamase Inhibitors and Inhibitor Combinations
Date and
Time: June 8, 2018 11:00 AM – 1:00 PM
Location: Exhibit
and Poster Hall, Building B, Halls B2-B5
Poster #606: Evaluation of Pharmacokinetics/Pharmacodynamics of
the novel β-lactamase inhibitor, ETX2514, in combination with sulbactam
against Acinetobacter baumannii
Session: 062 - AAR08
- New Antimicrobial Agents and New Research Technologies: New
β-lactamase Inhibitors and Inhibitor Combinations
Date and Time:
June 8, 2018 11:00 AM – 1:00 PM
Location: Exhibit and Poster
Hall, Building B, Halls B2-B5
Poster #1103: Structural Analyses of Inhibition of OXA-24 and
ADC-7 β-lactamases by ETX2514, A Novel Diazabicyclooctenone β-lactamase
Inhibitor (BLI)
Session: 097 - MBP16 - Structural Biology
Date
and Time: June 8, 2018 11:00 AM – 1:00 PM
Location:
Exhibit and Poster Hall, Building B, Halls B2-B5
ETX0282 Presentation:
Poster #603: The novel β-lactamase inhibitor ETX1317 effectively
restores the activity of cefpodoxime against extended spectrum
β-lactamase (ESBL)- and carbapenemase-expressing Enterobacteriaceae
isolated from recent urinary tract infections
Session: 062 -
AAR08 - New Antimicrobial Agents and New Research Technologies: New
β-lactamase Inhibitors and Inhibitor Combinations
Date and Time:
June 8, 2018 11:00 AM – 1:00 PM
Location: Exhibit and Poster
Hall, Building B, Halls B2-B5
Discovery Platform Presentation:
Oral Presentation: Addressing the Challenge of Gram-negative
Permeation in Antibacterial Discovery
Session: 123 - Riddles
and Rules of Gram-negative Permeation
Date and Time: June 8,
2018 1:30 PM – 2:15 PM
Location: Exhibit and Poster Hall,
Building B, Halls B2-B5, AAR Hub
About ETX2514SUL
ETX2514 is a novel broad-spectrum
intravenous inhibitor of class A, C and D β-lactamases. ETX2514 restores
the in vitro activity of multiple β-lactams against
Gram-negative, multidrug-resistant pathogens. Entasis is initially
developing ETX2514SUL, a fixed-dose combination of ETX2514 and
sulbactam, for the treatment of a variety of serious multidrug-resistant
infections caused by A. baumannii. Sulbactam is a generic
β-lactam that has intrinsic antibacterial activity against A.
baumannii but suffers from widespread β-lactamase-mediated
resistance. In preclinical studies, ETX2514 restored sulbactam
antibacterial activity against A. baumannii. ETX2514 has
completed single- and multi-ascending dose Phase 1 trials. The U.S. Food
and Drug Administration has granted Qualified Infectious Disease Product
(QIDP) designation and Fast Track designation to ETX2514SUL for the
treatment of hospital-acquired and ventilator-acquired bacterial
pneumonia and bloodstream infections due to A. baumannii.
About ETX0282CPDP
ETX0282 is an orally available, broad
spectrum inhibitor of class A and C β-lactamases. Entasis is developing
ETX0282 in combination with cefpodoxime proxetil, an orally available
cephalosporin approved for treatment of a variety of bacterial
infections. Cefpodoxime’s clinical utility is currently limited by
β-lactamase-mediated resistance. In preclinical studies, ETX0282
restored cefpodoxime’s antimicrobial activity against a variety of
pathogens, including Enterobacteriaceae resistant to
fluoroquinolones, cephalosporins and carbapenems. Entasis is initially
developing ETX0282CPDP, the combination of ETX0282 and cefpodoxime
proxetil, for the treatment of infections caused by Enterobacteriaceae,
including multidrug-resistant and carbapenem-resistant Enterobacteriaceae
(CRE). ETX0282CPDP is partially supported by an award from the Combating
Antibiotic Resistant Bacteria Biopharmaceutical Accelerator program
(CARB-X).
About Entasis Therapeutics Inc.
Entasis is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel antibacterial products to treat serious
infections caused by multidrug-resistant Gram-negative bacteria.
Entasis’ targeted-design platform has produced a pipeline of product
candidates, including ETX2514SUL (targeting A. baumannii
infections), ETX0282CPDP (targeting Enterobacteriaceae
infections), and zoliflodacin (targeting Neisseria gonorrhoeae).
Entasis is also using its platform to develop a novel class of
non-β-lactam penicillin-binding protein inhibitors (NBPs) targeting
Gram-negative infections. For more information, visit www.entasistx.com.
